KDR and small cell lung carcinoma: Anlotinib, an orally administered tyrosine kinase inhibitor of VEGFR and other growth factor receptors, was recently approved by the China FDA as a third-line therapy for Chinese patients with SCLC following clinical trials (ALTER 1202 study) [46, 47]; however, to date no anti-angiogenic agents have received regulatory approval in the US for treatment of SCLC.